# A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

> **NCT02310763** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 121 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** PF-06252616
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02310763
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-24
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-11-23
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** Termination Date 30AUG2018: Reason for termination: Lack of Efficacy
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02310763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02310763, "A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02310763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*